MARKET

VINC

VINC

Vincerx Pharma Inc
NASDAQ
0.8690
+0.0190
+2.24%
After Hours: 0.8759 +0.0069 +0.79% 19:52 04/22 EDT
OPEN
0.8800
PREV CLOSE
0.8500
HIGH
0.8800
LOW
0.8200
VOLUME
325.00K
TURNOVER
0
52 WEEK HIGH
9.37
52 WEEK LOW
0.6100
MARKET CAP
18.61M
P/E (TTM)
-0.4608
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at VINC last week (0415-0419)?
Weekly Report · 18h ago
Weekly Report: what happened at VINC last week (0408-0412)?
Weekly Report · 04/15 11:23
Vincerx Pharma Inc (VINC) Gets a Buy from Leerink Partners
TipRanks · 04/10 06:21
Crude Oil Down Over 1%; Cognyte Software Shares Plummet
U.S. Stocks traded lower toward the end of trading on Tuesday. The Dow traded down 0.46% while the NASDAQ fell 0.24%. The S&P 500 fell around 0.4% and European shares closed lower. Real estate shares jumped by 0.8% in Asian markets. The NFIB Small Business Optimism Index declined for a third straight month.
Benzinga · 04/09 18:34
BUZZ-U.S. STOCKS ON THE MOVE-Chemours, Lucid, OppFi
U.S. Stocks reverse early gains ahead of key inflation print. Dow Jones Industrial Average down 0.36%; S&P 500 and Nasdaq Composite also down. Chemours, Lucid, OppFi among the top stocks on the move. Lucid Group down 3.9% after announcing potential sale of parts of company.
Reuters · 04/09 18:19
Vincerx (VINC) Tumbles on Results From Cancer Therapy Study
NASDAQ · 04/09 17:34
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Tilray Brands, Inc. (NASDAQ:TLRY) fell sharply during Tuesday's session. The company missed third-quarter estimates and said it no longer expects to generate positive free cash flow for the full fiscal year 2024. Laser Photonics Corporation shares climbed 168% to $3.82.
Benzinga · 04/09 17:12
12 Health Care Stocks Moving In Tuesday's Intraday Session
Acrivon Therapeutics (NASDAQ:ACRV) stock moved upwards by 72.0% to $10.16 during Tuesday's regular session. BioSig Technologies stock increased by 27.41% and Tilray Brands stock decreased by 19.5%. The company's Q4 earnings report came out yesterday.
Benzinga · 04/09 16:31
More
About VINC
Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. It has a next generation bioconjugation platform, called VersAptx. The VersAptx platform is a versatile and adaptable, next generation bioconjugation platform. Its product candidates include VIP943 (CD123-KSPi), VIP924 (CXCR5-KSPi), VIP236, and Enitociclib (P-TEFb/CDK9 inhibitor). VIP943 is a potential anti-CD123 ADC created with its VersAptx Platform. It consists of an anti-CD123 antibody, a novel legumain-cleavable linker, and a KSPi payload enhanced with its CellTrapper technology. Enitociclib is a selective CDK9 inhibitor. Enitociclib effectively blocks P-TEFb-mediated activation of RNA polymerase II, preventing transcription of MCL1 and MYC, proteins associated with poor prognosis in various types of cancer.

Webull offers Vincerx Pharma Inc stock information, including NASDAQ: VINC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VINC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VINC stock methods without spending real money on the virtual paper trading platform.